Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Spectrum Pharmaceuticals, Inc.    SPPI

SPECTRUM PHARMACEUTICALS, INC. (SPPI)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/14/2018 06/15/2018 06/18/2018 06/19/2018 06/20/2018 Date
20(c) 19.95(c) 19.89(c) 19.96(c) 20.35 Last
1 527 892 2 571 380 1 243 659 2 003 224 2 395 881 Volume
+0.15% -0.25% -0.30% +0.35% +1.95% Change
More quotes
Financials (USD)
Sales 2018 109 M
EBIT 2018 -89,8 M
Net income 2018 -109 M
Debt 2018 -
Yield 2018 -
Sales 2019 113 M
EBIT 2019 -85,9 M
Net income 2019 -98,9 M
Debt 2019 -
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales2018 18,9x
Capi. / Sales2019 18,2x
Capitalization 2 070 M
More Financials
Company
Spectrum Pharmaceuticals, Inc. is a biotechnology company, which engages in the acquisition, development, and commercialization of pipeline of late-stage clinical and commercial products.It operates through the following brands: FOLOTYN, ZEVALIN, MARQIBO, BELEODAQ, and EVOMELA.The company was... 
More about the company
Surperformance© ratings of Spectrum Pharmaceuticals,
Trading Rating : Investor Rating :
More Ratings
Latest news on SPECTRUM PHARMACEUTICALS,
06/18SPECTRUM PHARMACEUTICALS INC : Change in Directors or Principal Officers, Amendm..
AQ
06/07SPECTRUM PHARMACEUTICALS, INC. : Today's Research Reports on Trending Tickers: S..
AC
06/01SPECTRUM PHARMACEUTICALS : to Present Corporate Update at the Jefferies 2018 Glo..
AQ
05/30SPECTRUM PHARMACEUTICALS : to Present Corporate Update at the Jefferies 2018 Glo..
BU
05/25SPECTRUM PHARMACEUTICALS : Announces Detailed Results from Phase 3 Study of ROLO..
AQ
05/17SPECTRUM PHARMACEUTICALS : to Present Corporate Update at the Bank of America Me..
AQ
05/16SPECTRUM PHARMACEUTICALS : CORRECTING and REPLACING Spectrum Pharmaceuticals Ann..
BU
05/15SPECTRUM PHARMACEUTICALS : to Present Corporate Update at the Bank of America Me..
AQ
05/10SPECTRUM PHARMACEUTICALS : Announces Corporate Governance Enhancements and Board..
AQ
05/10SPECTRUM PHARMACEUTICALS : Announces Exclusive Licensing Agreement on Certain Me..
AQ
More news
Sector news : Biotechnology & Medical Research - NEC
02:59pGILEAD SCIENCES : GSK takes billion-dollar drug fight with Gilead to top AIDS me..
RE
08:02aLatecomer Sanofi looks to catch next wave of cancer therapies
RE
06/19Alexion Uses FDA Priority-Review Voucher for Blood Disorder
DJ
06/13Sanofi says on track to regain solid position in cancer drugs
RE
06/12GSK says vaccine business president to leave by year-end
RE
More sector news : Biotechnology & Medical Research - NEC
Latest Tweets
10:08pSpectrum Pharmaceuticals, Inc. $SPPI Given Consensus Recommendation of “Buy” .. 
07:36p$SPPI coming out of a big coil 
06/19$SPPI New Form 3 for Spectrum Pharmaceuticals, Inc. From our Stock News Alert.. 
06/19$SPPI New Form 3 for Spectrum Pharmaceuticals, Inc. From our Stock News Alert.. 
06/18$SPPI New Form S-8 POS for Spectrum Pharmaceuticals, Inc. From our Stock News.. 
More tweets
Qtime:50
News from SeekingAlpha
06/08EC OKs AstraZeneca's Tagrisso for first-line lung cancer 
06/06ROUNDS REPORT : Melinta Rallied While Novavax Experienced Significant Insider Pu.. 
05/21ONCOMED PHARMACEUTICALS : Assessing The Prospect Of A Potential Robust Winner 
05/18YOUR DAILY PHARMA SCOOP : RARE Shows Solid Data, Spectrum Up On Positive Results.. 
05/18ROUNDS REPORT : Eiger Moved Northbound While Spectrum Rallied Strongly Due To AD.. 
Chart SPECTRUM PHARMACEUTICALS,
Duration : Period :
Spectrum Pharmaceuticals,  Technical Analysis Chart | SPPI | US84763A1088 | 4-Traders
Technical analysis trends SPECTRUM PHARMACEUTICALS,
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Average target price 29,3 $
Spread / Average Target 47%
EPS Revisions
Managers
NameTitle
Joseph W. Turgeon President, Chief Executive Officer & Director
Stuart Mitchell Krassner Chairman
Thomas J. Riga Executive VP, Chief Operating & Commercial Officer
Kurt A. Gustafson Chief Financial Officer & Executive Vice President
Guru Reddy Vice President-Preclinical Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
SPECTRUM PHARMACEUTICALS, INC.5.28%2 070
CELLTRION, INC.--.--%34 574
IQVIA HOLDINGS INC8.22%21 638
LONZA GROUP1.10%20 183
INCYTE CORPORATION-23.96%15 266
ALNYLAM PHARMACEUTICALS, INC.-17.65%10 678